Schedule 13G ownership disclosure

Janux Therapeutics Inc

Common Stock, $0.001 par value per share · CUSIP: 47103J105

Event date: 2026-11-10

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • W. Lawrence Hawkins

    Shares: 3,150,450 · Class: 5.15%

  • Prosight Fund, LP

    Shares: 155,022 · Class: 0.25%

  • Prosight Plus Fund, LP

    Shares: 525,319 · Class: 0.86%

  • Prosight Management, LP

    Shares: 3,144,200 · Class: 5.14%

  • Prosight Partners, LLC

    Shares: 3,144,200 · Class: 5.14%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001617201-26-000008
Form type
SCHEDULE 13G/A
Filer
Janux Therapeutics, Inc.
CIK
CIK 1817713
Filed
Nov 13, 2026
Reporting period
Nov 10, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub